Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.
Epistemonikos ID: 9e9ef9be82aed965d62ff675b735d31e9aee04b7
First added on: May 13, 2024